​Scientific Research Institutions

The company has established a scientific management system and process, formed a relatively complete technological innovation system, and carried out technological innovation under the direct leadership of the general manager of the company with the scientific research and development system as the core.

The institute has a strong technology, professional and teamwork spirit of the R & D team, with the concept of "scientific rigor, pioneering and innovative", actively carry out scientific research and development, and take independent research and development, commissioned research and development, cooperative development and other ways to promote the rapid industrialization of R & D projects.

The institute has advanced R&D equipment and a good scientific research environment, focusing on the development of new products in the fields of cardiovascular drugs, diabetes drugs, anti-infective drugs, and skin topical preparations.

In order to meet the rapid development needs of Jingfeng Group, we reasonably planned the product pipeline layout, injected more development vitality into the group, introduced strategic partners, and leveraged external brains to empower the strategic transformation of product research and development and the continuous improvement of research and development level.

R&D System

The company's research institute is composed of project management department, analysis department, preparation department and synthesis department. It is responsible for the research and development of the company's new products, project management, and process quality research and development. At present, the R&D team has more than 20 people.

At present, it undertakes 19 new product research and development projects and consistency evaluation projects.

The R&D team takes scientific rigor and pioneering innovation as the concept of drug development. In order to carry out research work efficiently, the institute carries out a weak matrix management model, carries out project-based management of R&D projects, and establishes and improves the R&D quality system to ensure the compliance of research work and the reliability of research data.

Scientific Research and Development

The R&D field covers the research and development of oral solids, topical preparations, nasal sprays and other series of preparations and APIs, and the products involve multiple therapeutic fields such as hypoglycemic, hypolipidemic, and anti-infection. In product research and development, we not only rely on the strength of our own technical team, but also cooperate extensively with domestic scientific research institutions to conduct research and development in the fields of drug process development and drug clinical research, and actively respond to the opportunities and challenges brought by the changes in the pharmaceutical industry pattern.

R&D Results

In April 2019, the approval notice of supplementary application for metformin hydrochloride tablets (Bioequivalence Evaluations) was obtained

In August 2021, the approval notice of supplementary application for captopril tablets (25mg&12.5mg) (Bioequivalence Evaluations) was obtained

In April 2023, the notice of approval of the supplementary application for calcium oxybenzenesulfonate capsule (Bioequivalence Evaluations) was obtained

In May 2023, the approval notice of supplementary application for amlodipine besylate tablets (Bioequivalence Evaluations) was obtained

In June 2023, the drug registration certificate of acarbose tablets (generic drug) was obtained

In August 2023, the approval notice of supplementary application for metformin hydrochloride sustained-release tablets (Bioequivalence Evaluations) was obtained